Developing a clinical strategy for cholesterol management in an era of unanswered questions (Q43718360)

26 November 2017

1 reference

title

Developing a clinical strategy for cholesterol management in an era of unanswered questions (English)

1 reference

26 November 2017

Ansell BJ

1

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

American Journal of Cardiology

26 November 2017

published in

1 reference

26 November 2017

volume

88

1 reference

26 November 2017

issue

4A

1 reference

26 November 2017

page(s)

25F-30F

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Maximizing the cost-effectiveness of lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Comparison of statins in hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (< or = 60 years) with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Low-Density Lipoprotein Cholesterol and the Risk of Dementia With Stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901874-4

10.1016/S0002-9149(01)01874-4

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference